Images not displaying correctly? View in browser 

Participate in a Short Survey on PARP-inhibitors

The Société Internationale d’Urologie (SIU) is pleased to support the Università di Torino in helping to disseminate its 3-minute survey to shed light on the current landscape of genetic testing and the use of PARP-inhibitors in different institutions. The answers will be acquired anonymously; the data will not be accessible to third parties and will be used only for scientific purposes.

The subject of how and when to use genetic tests and PARP-inhibitors in prostate cancer has become one of the hot topics in urology. Not all the institutions and countries are prepared for the widespread use of genetic testing (somatic and/or germline) and not all have access to PARP-inhibitors in their routine clinical practice.

The insights gathered from this survey will play a crucial role in identifying gaps in current practices to help improve patient care and outcomes in prostate cancer management.

Thank you for participating!

*By answering the questions, you consent to the use of the data for scientific purposes.

Copyright © 2024 Société Internationale d'Urologie, All rights reserved.
You are receiving this mail because you opted in. You can unsubscribe at any time.

Our mailing address is:
SIU Central Office 1155 Robert-Bourassa Blvd., Suite 1012 Montreal (Quebec) Canada H3B 3A7
Tel.: +1 514 875-5665 Fax: +1 514 875-0205

Want to change how you receive these emails?
You can unsubscribe from this list or edit your preferences.